Oxford Immunotec Announces Release of New National Tuberculosis Test Data and Screening Grant for High Risk Patients on World TB Day
(Thomson Reuters ONE) -
OXFORD, United Kingdom and MARLBOROUGH, Mass., March 23, 2017 (GLOBE NEWSWIRE)
-- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics
company focused on developing and commercializing proprietary tests for the
management of underserved immune-regulated conditions, today announced the
release of national T-SPOT®.TB test positivity rates within the United States
and United Kingdom, as well as a grant to support TB screening for high risk
patients.
Today, only active TB infections are reported to the Centers for Disease Control
and Prevention in the U.S. and National Health Services in the U.K. Patients
with latent TB infections far outnumber those with active TB disease, but
consolidating test results from multiple sources makes this challenging to
track.
Oxford Immunotec has compiled a unique data set of T-SPOT.TB test results for
both the United States and the United Kingdom through its Oxford Diagnostic
Laboratories®' testing services. This data provides a representative overview
of the positivity rate of T-SPOT.TB tests in 2016 by state and region, and is
shown in three heat maps:
* U.S. T-SPOT.TB test positive rates by state
* U.K. T-SPOT.TB test positive rates by region
* U.S. T-SPOT.TB test positive rates by state for customers who serve patients
at higher risk of developing active TB. (High risk populations in this data
set include contact investigations, refugees, HIV patients and patients on
immunosuppressive therapy.)
The U.S. data is publicly available by visiting http://info.tspot.com/odl-heat-
maps
The U.K. data is publicly available by visiting http://info.tspot.com/uk-odl-
heat-maps-0
Further, the Company announced that they have provided a grant for tuberculosis
screening to the Florida Department of Health - Hillsborough County. This grant
will allow the Florida Department of Health to screen up to 250 additional high-
risk patients on World TB Day.
About Oxford Immunotec
Oxford Immunotec Global PLC is a global, high-growth diagnostics company focused
on developing and commercializing proprietary tests for the management of
underserved immune-regulated conditions. The Company's first product is the T-
SPOT.TB test, which is used to test for tuberculosis infection. The T-
SPOT.TB test has been approved for sale in over 50 countries, including the
United States, where it has received pre-market approval from the Food and Drug
Administration, Europe, where it has obtained a CE mark, as well as Japan and
China. The Company's second product line is a range of assays for tick-borne
diseases, such as Lyme disease, obtained through the acquisitions of Imugen and
Immunetics. Also obtained through the acquisitions is the Company's third
product line focused on screening for Babesia in donated blood, for which the
Company is currently seeking FDA clearance. The T-SPOT.CMV test and the T-
SPOT.PRT test are pipeline products as part of the Company's fourth intended
product line focused on the transplantation market. In addition to these four
product lines, the Company has additional active development programs in other
immune-regulated conditions. The Company is headquartered near Oxford, U.K. and
in Marlborough, Mass. Additional information can be found
at www.oxfordimmunotec.com.
T-SPOT and the Oxford Immunotec logo are trademarks of Oxford Immunotec Ltd.
Immunetics is a trademark of Immunetics, Inc.
CONTACTS:
For Media Inquiries:
Caroline Crawley
Oxford Immunotec
Tel: +44 1235 442796
ccrawley(at)oxfordimmunotec.com
For Investor Inquiries:
Rick Altieri
Chief Financial Officer
Oxford Immunotec
Tel: +1 (508) 573-9953
raltieri(at)oxfordimmunotec.com
Mark Klausner
Westwicke Partners
Tel: +1 (443) 213-0501
oxfordimmunotec(at)westwicke.com
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Oxford Immunotec via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 23.03.2017 - 22:51 Uhr
Sprache: Deutsch
News-ID 532216
Anzahl Zeichen: 4657
contact information:
Town:
Oxfordshire
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 208 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Oxford Immunotec Announces Release of New National Tuberculosis Test Data and Screening Grant for High Risk Patients on World TB Day"
steht unter der journalistisch-redaktionellen Verantwortung von
Oxford Immunotec (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
